Summary Dengue was responsible for 36 100 deaths (95% UI 9180–44 500) and 2·38 million (0·828–3·27) DALYs in 2019. In southeast Asia in 2019, dengue had the highest DALY burden among all neglected tropical diseases and malaria.

Definition The estimates for dengue disease represent cases of clinically apparent illness (dengue fever, dengue haemorrhagic fever, dengue shock syndrome, and resulting chronic fatigue syndrome) and death. These estimates do not represent asymptomatic dengue virus infection.

Total sources
Incidence 1964
Prevalence 0
Remission 0
Causes of death 3432
Other 19
Table 1: Total sources used in GBD 2019 estimation
What is new in GBD 2019?
  • •A new systematic literature review identified 52 comparisons between active and passive case detection. Input data were adjusted for under-reporting using a Bayesian meta-analysis.
  • •Regional age patterns were developed to disaggregate all-age case notifications into age-specific incidence, accounting for the population structure of each location before modelling.
  • •A hybrid approach was employed in which ST-GPR and a negative binomial regression using fixed effects modelled the incidence of dengue disease, enabling data reported at both subnational and national levels to influence estimates.
Prevalence
Incidence
Deaths
YLLs
YLDs
DALYs
Cases
(millions)
Rate (per 100 000)
Cases
(millions)
Rate (per 100 000)
Deaths
(millions)
Rate (per 100 000)
YLLs
(millions)
Rate (per 100 000)
YLDs
(millions)
Rate (per 100 000)
DALYs
(millions)
Rate (per 100 000)
2019
Both Sexes
3·39
(2·17
to 6·04)
44·2
(28·1
to 79·2)
56·9
(37·1
to 101)
740·4
(478·2
to 1323·1)
0·0361
(0·00918
to 0·0445)
0·5
(0·1
to 0·6)
1·83
(0·482
to 2·32)
25·0
(6·6
to 31·8)
0·552
(0·279
to 1·10)
7·2
(3·6
to 14·4)
2·38
(0·828
to 3·27)
32·2
(11·1
to 44·2)
Females
1·75
(1·07
to 3·15)
45·9
(27·6
to 83·4)
29·4
(18·1
to 53·0)
769·9
(469·0
to 1392·9)
0·0170
(0·00358
to 0·0215)
0·4
(0·1
to 0·6)
0·842
(0·172
to 1·08)
23·4
(4·8
to 30·2)
0·284
(0·140
to 0·571)
7·5
(3·6
to 15·1)
1·13
(0·344
to 1·55)
30·8
(9·2
to 42·5)
Males
1·64
(1·06
to 2·90)
42·5
(27·4
to 75·4)
27·5
(18·1
to 48·3)
712·2
(466·5
to 1256·9)
0·0190
(0·00367
to 0·0239)
0·5
(0·1
to 0·6)
0·989
(0·189
to 1·28)
26·6
(5·1
to 34·6)
0·269
(0·138
to 0·526)
7·0
(3·6
to 13·7)
1·26
(0·362
to 1·73)
33·5
(9·5
to 46·3)
Percentage change 2010-19
Both Sexes
5·7%
(–24·2
to 75·9)
–3·5%
(–30·8
to 60·8)
5·6%
(–24·0
to 72·5)
–3·6%
(–30·6
to 57·3)
13·1%
(–7·7
to 36·4)
–0·4%
(–18·8
to 19·8)
–2·6%
(–20·6
to 21·2)
–10·0%
(–26·8
to 12·5)
5·7%
(–23·9
to 76·0)
–3·3%
(–30·2
to 61·4)
–0·8%
(–18·0
to 27·8)
–8·6%
(–24·6
to 18·4)
Females
5·4%
(–23·5
to 75·2)
–4·0%
(–30·3
to 60·3)
5·3%
(–23·6
to 72·7)
–4·1%
(–30·3
to 56·7)
12·1%
(–11·2
to 38·8)
–3·1%
(–23·1
to 20·4)
–7·3%
(–26·0
to 19·0)
–15·1%
(–32·3
to 10·1)
5·3%
(–23·8
to 76·2)
–3·8%
(–30·5
to 60·1)
–4·4%
(–22·7
to 25·6)
–12·6%
(–29·2
to 14·9)
Males
6·0%
(–24·9
to 76·1)
–3·0%
(–31·2
to 61·3)
5·9%
(–24·4
to 72·6)
–3·1%
(–30·8
to 57·9)
14·0%
(–9·1
to 38·3)
1·3%
(–18·7
to 22·2)
1·8%
(–19·4
to 28·0)
–5·4%
(–25·2
to 19·0)
6·0%
(–24·8
to 75·0)
–2·7%
(–30·7
to 60·4)
2·7%
(–17·1
to 31·2)
–4·9%
(–23·4
to 21·6)
Numbers in parentheses are 95% uncertainty intervals.
Table 2: Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths YLLs YLDs DALYs
1990 100th 81st 102nd 111th
2010 104th 89th 99th 120th
2019 101st 88th 99th 120th
Table 3: Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined
Figure 1: Composition of DALYs by YLLs and constituent sequelae YLDs for both sexes combined, 2019
No Legend
Figure 2: Age-standardised DALY rates for each location by SDI, both sexes combined, 2019
Figure 3: Composition of DALYs by YLLs and YLDs, age group, and sex, 2019
No Legend
Figure 4: Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019